公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial | Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S.; Im Y.-H.; CHIUN-SHENG HUANG ; Diéras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A. | Journal of Clinical Oncology | 307 | 277 | |
2021 | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE | Mamounas E. P.; Untch M.; Mano M. S.; CHIUN-SHENG HUANG ; Geyer C. E.; von Minckwitz G.; Wolmark N.; Pivot X.; Kuemmel S.; DiGiovanna M.P.; Kaufman B.; Kunz G.; Conlin A.K.; Alcedo J.C.; Kuehn T.; Wapnir I.; Fontana A.; Hackmann J.; Polikoff J.; Saghatchian M.; Brufsky A.; Yang Y.; Zimovjanova M.; Boulet T.; Liu H.; Tesarowski D.; Lam L.H.; Song C.; Smitt M.; Loibl S. | Annals of oncology : official journal of the European Society for Medical Oncology | 57 | 49 | |
2014 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | De Azambuja E.; Holmes A.P.; Piccart-Gebhart M.; Holmes E.; Di Cosimo S.; Swaby R.F.; Untch M.; Jackisch C.; Lang I.; Smith I.; Boyle F.; Xu B.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. | The Lancet Oncology | 387 | 330 | |
2020 | Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer | Conte P.; Schneeweiss A.; Loibl S.; Mamounas E.P.; von Minckwitz G.; Mano M.S.; Untch M.; CHIUN-SHENG HUANG ; Wolmark N.; Rastogi P.; D’Hondt V.; Redondo A.; Stamatovic L.; Bonnefoi H.; Castro-Salguero H.; Fischer H.H.; Wahl T.; Song C.; Boulet T.; Trask P.; Geyer C.E.; Jr. | Cancer | 16 | 12 | |
2005 | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Piccart-Gebhart M.J.; Procter M.; Leyland-Jones B.; Goldhirsch A.; Untch M.; Smith I.; Gianni L.; Baselga J.; Bell R.; Jackisch C.; Cameron D.; Dowsett M.; Barrios C.H.; Steger G.; CHIUN-SHENG HUANG ; Andersson M.; Inbar M.; Lichinitser M.; L?ng I.; Nitz U.; Iwata H.; Thomssen C.; Lohrisch C.; Suter T.M.; R?schoff J.; S?to T.; Greatorex V.; Ward C.; Straehle C.; McFadden E.; Dolci M.S.; Gelber R.D. | New England Journal of Medicine | 4386 | 3899 | |
2019 | Trastuzumab emtansine for residual invasive HER2-positive breast cancer | Von Minckwitz G.; CHIUN-SHENG HUANG ; Mano M.S.; Loibl S.; Mamounas E.P.; Untch M.; Wolmark N.; Rastogi P.; Schneeweiss A.; Redondo A.; Fischer H.H.; Jacot W.; Conlin A.K.; Arce-Salinas C.; Wapnir I.L.; Jackisch C.; DiGiovanna M.P.; Fasching P.A.; Crown J.P.; W?lfing P.; Shao Z.; Caremoli E.R.; Wu H.; Lam L.H.; Tesarowski D.; Smitt M.; Douthwaite H.; Singel S.M.; Geyer C.E.; Jr. | New England Journal of Medicine | 1510 | 1351 |